For more than 20 years, Karl Schmieder advised leading life sciences companies on how to tell their story to the multiple audiences they need to engage. From two-man start-ups to Fortune 10 pharma companies, Karl has helped companies make the transition from mass-marketing to personalized digital engagement strategies.
Synthetic biology – the next iteration of biotech – is applying the principles of engineering to biotechnology, making it more accessible and impacting all levels of business.
A sought-after speaker and writer, Karl lectures regularly at NYU and teaches businesses how to to prepare for the age of engineered biology. He teaches thought leadership strategies to compani…